TITLE

Model-based parametric study of frontostriatal abnormalities in schizophrenia patients

AUTHOR(S)
Tanaka, Shoji
PUB. DATE
January 2010
SOURCE
BMC Psychiatry;2010, Vol. 10, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Several studies have suggested that the activity of the prefrontal cortex (PFC) and the dopamine (DA) release in the striatum has an inverse relationship. One would attribute this relationship primarily to the circuitry comprised of the glutamatergic projection from the PFC to the striatum and the GABAergic projection from the striatum to the midbrain DA nucleus. However, this circuitry has not characterized satisfactorily yet, so that no quantitative analysis has ever been made on the activities of the PFC and the striatum and also the DA release in the striatum. Methods: In this study, a system dynamics model of the corticostriatal system with dopaminergic innervations is constructed to describe the relationships between the activities of the PFC and the striatum and the DA release in the striatum. By taking published receptor imaging data from schizophrenia patients and healthy subjects into this model, this article analyzes the effects of striatal D2 receptor activation on the balance of the activity and neurotransmission in the frontostriatal system of schizophrenic patients in comparison with healthy controls. Results: The model predicts that the suppressive effect by D2 receptors at the terminals of the glutamatergic afferents to the striatum from the PFC enhances the hypofrontality-induced elevation of striatal DA release by at most 83%. The occupancy-based estimation of the 'optimum' D2 receptor occupancy by antipsychotic drugs is 52%. This study further predicts that patients with lower PFC activity tend to have greater improvement of positive symptoms following antipsychotic medication. Conclusion: This model-based parametric study would be useful for system-level analysis of the brains with psychiatric diseases. It will be able to make reliable prediction of clinical outcome when sufficient data will be available.
ACCESSION #
49160242

 

Related Articles

  • WAY-100635 is a potent dopamine D4 receptor agonist. Chemel, Benjamin R.; Roth, Bryan L.; Armbruster, Blaine; Watts, Val J.; Nichols, David E. // Psychopharmacology;Oct2006, Vol. 188 Issue 2, p244 

    WAY-100635 is a prototypical 5-HT1A receptor antagonist and has been used widely as a pharmacological probe to investigate the distribution and function of 5-HT1A receptors. Results from our studies suggested that WAY-100635 was potently inducing effects unrelated to its 5-HT1A receptor...

  • Antidepressant-Like Effect of D2/3 Receptor-, but not D4 Receptor-Activation in the Rat Forced Swim Test. Basso, Ana M; Gallagher, Kelly B; Bratcher, Natalie A; Brioni, Jorge D; Moreland, Robert B; Hsieh, Gin C; Drescher, Karla; Fox, Gerard B; Decker, Michael W; Rueter, Lynne E // Neuropsychopharmacology;Jul2005, Vol. 30 Issue 7, p1257 

    Dopamine plays a role in the pathophysiology of depression and therapeutic effects of antidepressants but the contribution of individual D2-like receptor subtypes (D2, D3, D4) to depression is not known. We present evidence that activation of D2/D3, but not D4 receptors, can affect the outcome...

  • Combo therapy helps beat the blues in Spain.  // PharmacoEconomics & Outcomes News;2/25/2006, Issue 497, p7 

    Discusses research on the use of antidepressant combinations in Spain. Reference to a study by J. De la Gádara et al, published in a 2005 issue of the "Acta Psychiatrica Scandinavica Supplementum"; Findings of the study.

  • Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants). Skolnick, Phil; Basile, Anthony S. // CNS & Neurological Disorders - Drug Targets;2007, Vol. 6 Issue 2, p141 

    The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This...

  • Regional Differences in Extracellular Dopamine and Serotonin Assessed by In Vivo Microdialysis in Mice Lacking Dopamine and/or Serotonin Transporters. Hao-wei Shen; Hagino, Yoko; Kobayashi, Hideaki; Shinohara-Tanaka, Keiko; Ikeda, Kazutaka; Yamamoto, Hideko; Yamamoto, Toshifumi; Lesch, Klaus-Peter; Murphy, Dennis L.; Hall, F. Scott; Uhl, George R.; Sora, Ichiro // Neuropsychopharmacology;Oct2004, Vol. 29 Issue 10, p1790 

    Cocaine conditioned place preference (CPP) is intact in dopamine transporter (DAT) knockout (KO) mice and enhanced in serotonin transporter (SERT) KO mice. However, cocaine CPP is eliminated in double-KO mice with no DAT and either no or one SERT gene copy. To help determine mechanisms...

  • Dopamine and Serotonin Receptor Binding and Antipsychotic Efficacy. Richtand, Neil M.; Welge, Jeffrey A.; Logue, Aaron D.; Keck Jr., Paul E.; Strakowski, Stephen M.; McNamara, Robert K. // Neuropsychopharmacology;Aug2007, Vol. 32 Issue 8, p1715 

    The relationship between clinically effective antipsychotic drug dosage and binding affinity to cloned dopamine (DA) and serotonin receptor subtypes was analyzed in an effort to elucidate the contribution of individual receptor subtypes to medication response. Clinically effective dose and...

  • Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like Effects. Le Foll, Bernard; Sokoloff, Pierre; Stark, Holger; Goldberg, Steven R. // Neuropsychopharmacology;Apr2005, Vol. 30 Issue 4, p720 

    Environmental stimuli previously paired with drug taking appear to play a critical role in nicotine dependence. Converging anatomical, pharmacological, and behavioral evidence implicates dopamine D3 receptors (D3Rs) in the mechanisms underlying stimulus-controlled drug-seeking behavior. This...

  • Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients. Schmitt, G. J. E.; Frodl, T.; Dresel, S.; La Fougère, C.; Bottlender, R.; Koutsouleris, N.; Hahn, K.; Möller, H. -J.; Meisenzahl, E. M. // European Archives of Psychiatry & Clinical Neuroscience;2006, Vol. 256 Issue 2, p115 

    Discusses data which supports evidence that differences in presynaptic dopaminergic activity in schizophrenic patients are associated with the extend of the acute psychotic syndrome. Role being played by the membrane bound presynaptic dopamine transporter in regulating the dopamine content in...

  • Glutamate and Schizophrenia. Van Berckel, B. N. M. // Current Neuropharmacology;Dec2003, Vol. 1 Issue 4, p351 

    Schizophrenia is a complex and chronic disease that affects multiple aspects of cognition and behavior, including attention, perception, thought processes, emotion and volition. However, the pathophysiology of schizophrenia has not yet been fully clarified. For more than a decade, the dopamine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics